Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and...

Descripción completa

Detalles Bibliográficos
Autores principales: Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Harari, Gil, Dolev, Mark, Menascu, Shay, Magalashvili, David, Flechter, Shlomo, Givon, Uri, Guber, Diana, Sonis, Polina, Zilkha-Falb, Rina, Gurevich, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500842/
https://www.ncbi.nlm.nih.gov/pubmed/34655991
http://dx.doi.org/10.1016/j.jneuroim.2021.577746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500842/
https://www.ncbi.nlm.nih.gov/pubmed/34655991
http://dx.doi.org/10.1016/j.jneuroim.2021.577746

Ejemplares similares